- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Apoptosis-Inducing Effect of a New Bisphosphonate, YM529, on Various Hematopoietic Tumor Cell Lines.
-
- Nishida Shozo
- Kinki University School of Pharmaceutical Sciences
-
- Kikuichi Shigeru
- Kinki University School of Pharmaceutical Sciences
-
- Haga Hisae
- Kinki University School of Pharmaceutical Sciences
-
- Yoshioka Shohei
- Kinki University School of Pharmaceutical Sciences
-
- Tsubaki Masonobu
- Kinki University School of Pharmaceutical Sciences
-
- Fujii Katsuki
- Kinki University School of Pharmaceutical Sciences
-
- Irimajiri Kiyohiro
- Kinki University School of Pharmaceutical Sciences
Search this article
Description
In recent years, it has been reported that bisphosphonates inhibited the cell cycle of myeloma cells to inhibit cell proliferation directly, and it was also reported that bisphosphonates induced apoptosis of myeloma cells in vitro. Recently, YM529 was developed as a new third-generation bisphosphonate. In our experiment, we investigated whether YM529 showed an antitumor effect on hematopoietic tumor cell lines other than myeloma, and we compared YM529 with YM175, which had a relatively more potent antitumor effect than that of existing bisphosphonates. We found that YM529 inhibited cell proliferation in various hematopoietic tumor cell lines (acute promyelocytic leukemia cell line HL-60, chronic myeloid leukemia cell line K562, histiocytic lymphoma cell line U937, lymphoblastic leukemia T cell line Jurkat, acute lymphoblastic leukemia T cell line MOLT-4, lymphoblastic leukemia B cell line CCRF-SB) including myeloma (myeloma cell line HS-Sultan) dose-dependently and time-dependently to a degree equivalent or superior to that in myeloma, and induced apoptosis at a lower concentration as compared with YM175. We confirmed many dead cells as well as apoptosis based on the detection of the nuclei with separate globular structure, the activation of caspase-3, and the decrease in mitochondrial transmembrane potential. Therefore, it is concluded that further utilization of YM529 can be expected against hematopoietic tumor cells in the future.
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 26 (1), 96-100, 2003
The Pharmaceutical Society of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679602073856
-
- NII Article ID
- 110003608298
-
- NII Book ID
- AA10885497
-
- COI
- 1:CAS:528:DC%2BD3sXjs1ejur8%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 6393820
-
- PubMed
- 12520182
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed